Keryx Biopharmaceuticals Inc. Sets New 1-Year High at $10.03 (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) set a new 52-week high during mid-day trading on Tuesday, American Banking & Market News reports. The stock traded as high as $10.03 and last traded at $10.00, with a volume of 4,175,276 shares. The stock had previously closed at $9.29.
KERX has been the subject of a number of recent research reports. Analysts at Maxim Group raised their price target on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from $9.00 to $12.00 in a research note to investors on Thursday, August 1st. They now have a “buy” rating on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in a research note to investors on Wednesday, June 19th. They set an “overweight” rating and a $13.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) in a research note to investors on Wednesday, June 19th. They now have a $13.00 price target on the stock.
Ten analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $12.00.
Keryx Biopharmaceuticals has a one year low of $2.23 and a one year high of $10.04. The stock’s 50-day moving average is $8.94 and its 200-day moving average is $8.09. The company’s market cap is $818.2 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.04. During the same quarter in the previous year, the company posted ($0.02) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.41 earnings per share for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.